Clinical trial studies safety and efficacy of adding a kinase inhibitor to chemotherapy with topotecan in small cell lung cancer
Small cell lung cancer (SCLC) is so named because the tumor cells are small relative to other carcinomas.
Dr. Anish Thomas, Staff Clinician in the Thoracic and Gastrointestinal Oncology Branch, is leading a trial of combination therapy in small cell lung cancer (SCLC), a fast-growing malignancy that occurs most commonly in smokers. Topotecan is a chemotherapy drug that damages cancer cells’ DNA, causing the cells to die, but it may stop working in some people over time. VX-970, a kinase inhibitor, may stop cancer cells from repairing the DNA damage caused by chemotherapy, which could improve treatment response. The goal of this study is to see if the combination of topotecan and VX-970 is safe for patients and effective against small cell lung cancer. Adults 18 and older may contact Linda Sciuto, RN, at 301-451-9707 to discuss eligibility. View protocol description.Summary Posted: 08/2016